Comera Life Sciences Holdings Inc. (CMRA)

Overview

Comera Life Sciences Holdings, Inc., rooted in the innovative fields of life sciences, stands as a preclinical stage company with a firm focus on the development of novel therapeutics. Leveraging its proprietary formulation platform, Comera Life Sciences aims to redefine treatment modalities by enabling the transformation of intravenous biologics into subcutaneous versions, thus potentially improving accessibility, patient compliance, and overall treatment experiences. Founded in the year 2014, and with its headquarters located in Woburn, Massachusetts, the company is at the forefront of creating alternative therapeutic options for patients, showcasing its commitment through its robust pipeline of proprietary therapeutics.

Products and Services

• SQore Platform

At the heart of Comera Life Sciences' innovative edge is its SQore platform, engineered to facilitate the conversion of intravenous biologics to subcutaneous administrations. This proprietary technology symbolizes a leap forward in pharmaceutical formulation, aiming to make therapies more accessible and less invasive for patients. The SQore platform is a testament to Comera's dedication to revolutionizing drug delivery methods, emphasizing patient-centered care.

• CLS-001

Leading the charge in Comera's pipeline is CLS-001, a pioneering subcutaneous formulation of vedolizumab. This therapeutic candidate stands as a beacon of hope for individuals suffering from inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. By focusing on the subcutaneous delivery of vedolizumab, CLS-001 aims to offer an innovative, patient-friendly treatment alternative, potentially enhancing the quality of life for patients grappling with these chronic conditions. Comera's commitment to addressing the needs of the inflammatory bowel disease community through CLS-001 underscores its broader mission to improve healthcare outcomes with cutting-edge biopharmaceutical solutions.